IL17A and autoimmune disease: In the present study, we describe for the first time to our knowledge that SF CD1c+ cDC from patients with RA preferentially display a high capability to activate pathogenic IL-17+IFN-γ+CD4+ T cells involved in autoimmune diseases (8–10).